Clinical Activity and Safety of IDH2 Inhibitor Enasidenib (AG-221) in IDH2-Mutant Relapsed/Refractory AML
Slideset - Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 12, 2017 Category: Hematology Source Type: research
Phase I Trial of CD19-Targeted 19-28z CAR T-Cell Therapy in Adult Pts With R/R B-Cell ALL
Slideset - Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 12, 2017 Category: Hematology Source Type: research
Clinical Activity and Safety of IDH2 Inhibitor Enasidenib (AG-221) in IDH2-Mutant Relapsed/Refractory AML
Slideset - Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 12, 2017 Category: Hematology Source Type: research
Preview of ASCO 2017: Top Expert-Selected Studies
Discussion - Look for these important studies at the upcoming Clinical Oncology meeting in Chicago. Be sure to also check our Web site frequently for downloadable PowerPoint slides featuring key presented data. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - May 31, 2017 Category: Hematology Source Type: research
Slideset
- (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - April 20, 2017 Category: Hematology Source Type: research
Managing Tumor Lysis Syndrome
Slideset - In this downloadable slideset, Anas Younes, MD, discusses standards of care for patients with or at risk of TLS, including risk stratification and optimal use of available agents for prophylaxis and management of TLS. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - April 17, 2017 Category: Hematology Source Type: research
Managing Tumor Lysis Syndrome
Slideset - In this downloadable slideset, Anas Younes, MD discusses standards of care for patients with or at risk of TLS, including risk stratification and optimal use of available agents for prophylaxis and management of TLS. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - April 17, 2017 Category: Hematology Source Type: research
Managing Treatment-Related Diarrhea in a Patient With MDS: A Case Study
Discussion - In this interesting case study, Donald P. Kotler, MD, examines the possible causes and solutions for lenalidomide-related diarrhea in a patient with myelodysplastic syndromes. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - March 31, 2017 Category: Hematology Source Type: research
Managing Cytokine Release Syndrome
Clinical Focus - In this CME/CE-certified module, Jae H. Park, MD, discusses the association of novel anticancer agents with cytokine release syndrome and reviews optimal current assessment, prevention, and treatment. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - March 10, 2017 Category: Hematology Source Type: research
Managing Cytokine Release Syndrome
Slideset - In this downloadable slideset, Jae H. Park, MD, discusses the association of novel anticancer agents with cytokine release syndrome and reviews optimal current assessment, prevention, and treatment. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - March 10, 2017 Category: Hematology Source Type: research
Managing Cytokine Release Syndrome
Clinical Focus - In this CME/CE-certified module, Jae H. Park, MD, discusses the association of novel anticancer agents with cytokine release syndrome and reviews optimal current assessment, prevention, and treatment. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - March 10, 2017 Category: Hematology Source Type: research
Expert Perspective on Practice-Changing Advances in Induction Therapy for High-Risk AML in Older Patients
Slideset - In this downloadable slideset, Jeffrey E. Lancet, MD, reviews key data regarding optimal induction treatments for older patients with high-risk acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - February 28, 2017 Category: Hematology Source Type: research
Expert Perspectives on Practice-Changing Advances in Induction Therapy for High-Risk AML in Older Patients
Clinical Focus - In this interactive, CME/CE-certified module, Jeffrey E. Lancet, MD, explores new approaches with induction therapy that may improve outcomes for older, high-risk patients with acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - February 28, 2017 Category: Hematology Source Type: research
New Findings in Leukemias
Learning Module - In this text module and accompanying downloadable slideset, experts review the most clinically relevant study results presented at Hematology 2016 in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - February 13, 2017 Category: Hematology Source Type: research
